Comment on CMS-2026-1255-0001

Summary: The Obesity Medicine Association (OMA) supports the proposed rules regarding API interoperability standards, electronic prior authorization for drugs, and increased transparency for denial reasons and metrics. However, they oppose the removal of formulary information from certain APIs and urge CMS to pursue a 24-hour maximum response timeframe for prior authorizations to ensure continuity of care for obesity medications.